Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improved breast cancer therapy (I-BCT-1)
2024-515087-31-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Sep 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of carboplatin in breast cancer, sponsored by Oslo University Hospital. Primary endpoint: Genomic tumor architecture and tumor cell heterogeneity. Planned start Sep 2024; status: authorised.
02
Drugs
carboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-515087-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515087-31-00.